In a large Phase 2 clinical trial involving adults with obesity: Participants experienced up to 17.5% average weight reduction at 24 weeks Weight loss reached approximately 24.2% at 48 weeks at higher doses (Lilly Investor Relations) Subsequent late-stage studies have suggested even greater reductions over longer periods, reinforcing the potential of triple-agonist therapies in metabolic medicine
This is incredibly beneficial for health improvement but may not be enough for individuals with severe or complex obesity
I have received many inquiries from current clients about the pros and cons of semaglutide and the impact the medication could have upon their mental health
MEN2) Cancer history (personal + family) GI/pancreatitis & gallbladder history Mental health conditions multi-select Diabetes (insulin / non-insulin / prediabetes) Primary care provider continuity check USPSTF-style lifestyle trial (150 min/wk for 6 months) Ros intake does not use a validated PHQ-2 or PHQ-9 depression screen depression is only a checkbox in a larger mental-health list
Francesco Giorgino, MD, an investigator on the ACHIEVE-5 trial, offered a longer-term perspective on orforgliprons potential in an interview published by Medscape Medical News, noting that its small-molecule structure makes it significantly easier to manufacture than peptide-based GLP-1 drugs
Overall, clinical trials consistently demonstrate a dose-dependent effect, with higher maintenance doses producing greater average weight loss
